Literature DB >> 14742674

Identification of a novel polymorphic enhancer of the human CYP3A4 gene.

Keiko Matsumura1, Tetsuya Saito, Yoshiki Takahashi, Takeshi Ozeki, Kazuma Kiyotani, Masaki Fujieda, Hiroshi Yamazaki, Hideo Kunitoh, Tetsuya Kamataki.   

Abstract

CYP3A4, the most abundant form of cytochrome P450 in the human adult liver, shows wide interindividual variation in its activity. This variability is thought to be caused largely by transcriptional and genetic factors, yet the underlying mechanisms are poorly understood. The purpose of this study was to clarify the mechanisms controlling the CYP3A4 gene transcription and to search for genetic polymorphisms in the 5'-flanking region of the CYP3A4 gene. Transient transfection of human hepatoma HepG2 cells and of normal human hepatocytes with a series of CYP3A4 promoter-luciferase reporter plasmids revealed that a region from -11.4 to -10.5 kilobases, designated the constitutive liver enhancer module of CYP3A4 (CLEM4), was important for the constitutive activation of the CYP3A4 gene. Gel shift assay using nuclear extracts prepared from HepG2 cells showed that HNF-1alpha, HNF-4alpha, USF1, and AP-1 interacted with CLEM4. Furthermore, the introduction of mutations into their binding sites demonstrated that essentially all sites were required for the maximal enhancer activity. Screening for genetic polymorphisms within CLEM4 in genomic DNA from French persons, we identified the novel variant, TGT insertion between -11,129 and -11,128 (-11,129_-11,128insTGT), whose allele frequency was 3.1%. The -11,129_-11,128insTGT resulted in the disruption of USF1 binding and a 36% reduction of the enhancer activity. These results suggest that CLEM4 is a constitutive enhancer of the CYP3A4 gene in the liver and that -11,129_-11,128insTGT may at least partly contribute to the interindividual variability of CYP3A4 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742674     DOI: 10.1124/mol.65.2.326

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Bernard H Shapiro
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

2.  Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.

Authors:  Nicholas L Giebel; Jeffrey D Shadley; D Gail McCarver; Kenneth Dorko; Roberto Gramignoli; Stephen C Strom; Ke Yan; Pippa M Simpson; Ronald N Hines
Journal:  Drug Metab Dispos       Date:  2016-02-26       Impact factor: 3.922

3.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.

Authors:  D Wang; Y Guo; S A Wrighton; G E Cooke; W Sadee
Journal:  Pharmacogenomics J       Date:  2010-04-13       Impact factor: 3.550

4.  Genetic analysis of drug metabolizing phase-I enzymes CYP3A4 in Tibetan populations.

Authors:  Lijun Liu; Yu Chang; Shuli Du; Xugang Shi; Hua Yang; Longli Kang; Tianbo Jin; Dongya Yuan; Yongjun He
Journal:  J Genet       Date:  2017-06       Impact factor: 1.166

5.  CYP3A variation and the evolution of salt-sensitivity variants.

Authors:  E E Thompson; H Kuttab-Boulos; D Witonsky; L Yang; B A Roe; A Di Rienzo
Journal:  Am J Hum Genet       Date:  2004-10-18       Impact factor: 11.025

6.  The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha.

Authors:  Fu-Jun Liu; Xiulong Song; Dongfang Yang; Ruitang Deng; Bingfang Yan
Journal:  Biochem J       Date:  2008-01-01       Impact factor: 3.857

7.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

Review 8.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

9.  Pharmacogene regulatory elements: from discovery to applications.

Authors:  Robin P Smith; Ernest T Lam; Svetlana Markova; Sook Wah Yee; Nadav Ahituv
Journal:  Genome Med       Date:  2012-05-25       Impact factor: 11.117

10.  The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.

Authors:  Danxin Wang; Wolfgang Sadee
Journal:  J Pers Med       Date:  2012-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.